Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

US Treasury Hits Back On Inversions; Will Pfizer Fold?

This article was originally published in The Pink Sheet Daily

Executive Summary

Treasury announced new regulations aimed at blocking tax-motivated deals, leaving the largest mega-deal in the history of pharma hanging in the balance.


Related Content

How US Tax Plan Could Affect Global Pharma Manufacturing Networks
US Treasury’s Final Earnings Stripping Guidance Keeps Pressure On Inversions
Death And Tax Inversion: Policy Fight Won't Go Away, Now Spawning Lawsuits
How The Pfizer/Allegan Deal Got Done: Inside The Twists And Turns Of A Mega-Merger


Related Companies

Related Deals